Tarsus Pharmaceuticals, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Total revenues			16.2	17.4	24.1	57.0	56.7	55.4
Revenue growth			-71.5%	-68.6%	-27.8%
Cost of goods sold			0.6	0.6	0.1	0.1	0.1	0.0
Gross profit			15.6	16.8	24.0	57.0	56.6	55.4
Gross margin			96.6%	96.4%	99.6%	99.9%	99.9%	100.0%
Selling, general and administrative [+]			37.1	31.8	28.2	25.4	22.5	18.0
General and administrative			37.1	31.8	28.2	25.4	22.5	18.0
Research and development			40.6	39.9	37.5	41.7	41.3	39.0
Other operating expenses						2.0		2.0
EBITDA [+]			-61.8	-54.6	-42.1	-11.8	-8.9	-3.4
EBITDA growth			596.8%	1521.9%	200.3%	-56.0%
EBITDA margin			-382.8%	-314.1%	-174.5%	-20.8%	-15.7%	-6.1%
Depreciation and amortization			0.3	0.3	0.3	0.3	0.3	0.3
EBIT [+]			-62.1	-54.9	-42.4	-12.2	-9.2	-3.6
EBIT growth			576.0%	1415.7%	199.2%	-55.0%
EBIT margin			-384.4%	-315.6%	-175.7%	-21.3%	-16.2%	-6.5%
Interest expense, net [+]			0.1	0.5	0.3	0.0	0.0	0.0
Interest expense			1.5	0.9	0.3
Interest income			1.4	0.3		0.0	0.0	0.0
Other income (expense), net [+]			-1.1	-0.7	-1.4	-1.7	-1.3	-1.6
Other			0.1	0.1	0.0	-0.1	-0.1	-0.1
Pre-tax income			-63.3	-56.1	-44.1	-13.8	-10.4	-5.2
Income taxes			0.1	0.4	0.4	0.1	0.0	-0.3
Tax rate				-0.7%	-0.8%
Net income			-63.3	-56.5	-44.4	-13.8	-10.4	-4.9
Net margin			-392.1%	-325.0%	-184.1%	-24.2%	-18.4%	-8.8%

Basic EPS [+]			($2.75)	($2.62)	($2.16)	($0.67)	($0.62)	($0.39)
Growth			345.4%	568.8%	18.8%	-91.1%
Diluted EPS [+]			($2.75)	($2.62)	($2.12)	($0.65)	($0.59)	($0.37)
Growth			364.4%	607.7%	22.3%	-91.4%

Shares outstanding (basic) [+]			23.1	21.6	20.6	20.5	16.9	12.5
Growth			36.2%	73.1%	158.3%	476.5%
Shares outstanding (diluted) [+]			23.1	21.6	21.0	21.2	17.7	13.2
Growth			30.6%	63.6%	151.0%	496.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.